Academic and patient advocacy group collaborations in Dentatorubral-pallidoluysian atrophy (DRPLA)

Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare progressive brain disorder that can impact children and adults. In children, DRPLA can lead to difficulties walking, talking, eating, epilepsy, and progressive intellectual deterioration. In adults, it manifests as movement impairment, talking and eating difficulties, and dementia or behavior changes. 

Redenlab are supporting communication testing and analysis in two multi-domain assessment studies. One, collaborating with Boston Children’s Hospital, Harvard University and The University of Melbourne to measure novel treatment outcomes. The second is a multi-national natural history study across North America and Europe run by CureDRPLA and Ataxia UK.

Related Post

  • Posted on 25 July, 2025
    A new clinical trial has found early evidence that a metabolic therapy could improve outcomes for people with ataxia-telangiectasia (A-T),...
    • Posted on 21 July, 2025
      Could a 10-second speech test repeating “pa,” “ta,” “ka” be the key to earlier detection of Alzheimer’s risk? Our new...
      • Posted on 26 June, 2025
        Pain is deeply personal, yet universally expressed through speech. But what if speech isn’t just a way we describe pain,...